An Open-Label, Single-arm, Multicenter Phase I Study of SCH 54031 (Pegylated Interferon Alfa-2b) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma

Trial Profile

An Open-Label, Single-arm, Multicenter Phase I Study of SCH 54031 (Pegylated Interferon Alfa-2b) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Peginterferon alfa-2b (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 15 Mar 2017 Status changed from completed to discontinued after 118 weeks from the study start, during the maintenance phase, due to regulatory approval in Japan. .
    • 31 Mar 2016 Status changed from active, no longer recruiting to completed.
    • 16 Feb 2015 According to ClinicalTrials.gov record, protocol amended- patients receive only 6 micrograms/kg SC in the induction phase as compared to 3 or 6 micrograms/kg.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top